Clinical and Research Applications of Carotid Intima-Media Thickness

Research output: Contribution to journalArticle

Abstract

Cardiovascular imaging modalities such as coronary computed tomography, carotid ultrasonography, and cardiovascular magnetic resonance imaging are increasingly being used to measure cardiovascular disease progression. Imaging measures, most notably carotid intima-media thickness (CIMT), are being applied as surrogate markers for clinical end points such as myocardial infarction and death in clinical trials. Clinicians and their patients are faced with the challenge of evaluating these imaging measures for their efficacy and practicality in clinical practice, as well as in clinical trials. The investigators determined from a review of clinical trials and guidelines that CIMT measurement may be useful in evaluating cardiovascular disease risk in select patient populations but may not always be an appropriate surrogate for clinical end points. In conclusion, although CIMT has clear advantages over alternative cardiovascular imaging modalities, ultimately, prospective trials comparing the effectiveness of CIMT as a predictive tool of cardiovascular risk with that of other novel markers would best direct clinical recommendations for this imaging measure.

Original languageEnglish (US)
Pages (from-to)1316-1320
Number of pages5
JournalThe American Journal of Cardiology
Volume103
Issue number9
DOIs
StatePublished - May 1 2009

Fingerprint

Carotid Intima-Media Thickness
Clinical Trials
Research
Cardiovascular Diseases
Biomarkers
Disease Progression
Ultrasonography
Myocardial Infarction
Tomography
Research Personnel
Magnetic Resonance Imaging
Guidelines
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clinical and Research Applications of Carotid Intima-Media Thickness. / Sharma, Kavita; Blaha, Michael; Blumenthal, Roger S; Musunuru, Kiran.

In: The American Journal of Cardiology, Vol. 103, No. 9, 01.05.2009, p. 1316-1320.

Research output: Contribution to journalArticle

@article{1efdd9a893544ce4ada5d237e52d9130,
title = "Clinical and Research Applications of Carotid Intima-Media Thickness",
abstract = "Cardiovascular imaging modalities such as coronary computed tomography, carotid ultrasonography, and cardiovascular magnetic resonance imaging are increasingly being used to measure cardiovascular disease progression. Imaging measures, most notably carotid intima-media thickness (CIMT), are being applied as surrogate markers for clinical end points such as myocardial infarction and death in clinical trials. Clinicians and their patients are faced with the challenge of evaluating these imaging measures for their efficacy and practicality in clinical practice, as well as in clinical trials. The investigators determined from a review of clinical trials and guidelines that CIMT measurement may be useful in evaluating cardiovascular disease risk in select patient populations but may not always be an appropriate surrogate for clinical end points. In conclusion, although CIMT has clear advantages over alternative cardiovascular imaging modalities, ultimately, prospective trials comparing the effectiveness of CIMT as a predictive tool of cardiovascular risk with that of other novel markers would best direct clinical recommendations for this imaging measure.",
author = "Kavita Sharma and Michael Blaha and Blumenthal, {Roger S} and Kiran Musunuru",
year = "2009",
month = "5",
day = "1",
doi = "10.1016/j.amjcard.2009.01.020",
language = "English (US)",
volume = "103",
pages = "1316--1320",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Clinical and Research Applications of Carotid Intima-Media Thickness

AU - Sharma, Kavita

AU - Blaha, Michael

AU - Blumenthal, Roger S

AU - Musunuru, Kiran

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Cardiovascular imaging modalities such as coronary computed tomography, carotid ultrasonography, and cardiovascular magnetic resonance imaging are increasingly being used to measure cardiovascular disease progression. Imaging measures, most notably carotid intima-media thickness (CIMT), are being applied as surrogate markers for clinical end points such as myocardial infarction and death in clinical trials. Clinicians and their patients are faced with the challenge of evaluating these imaging measures for their efficacy and practicality in clinical practice, as well as in clinical trials. The investigators determined from a review of clinical trials and guidelines that CIMT measurement may be useful in evaluating cardiovascular disease risk in select patient populations but may not always be an appropriate surrogate for clinical end points. In conclusion, although CIMT has clear advantages over alternative cardiovascular imaging modalities, ultimately, prospective trials comparing the effectiveness of CIMT as a predictive tool of cardiovascular risk with that of other novel markers would best direct clinical recommendations for this imaging measure.

AB - Cardiovascular imaging modalities such as coronary computed tomography, carotid ultrasonography, and cardiovascular magnetic resonance imaging are increasingly being used to measure cardiovascular disease progression. Imaging measures, most notably carotid intima-media thickness (CIMT), are being applied as surrogate markers for clinical end points such as myocardial infarction and death in clinical trials. Clinicians and their patients are faced with the challenge of evaluating these imaging measures for their efficacy and practicality in clinical practice, as well as in clinical trials. The investigators determined from a review of clinical trials and guidelines that CIMT measurement may be useful in evaluating cardiovascular disease risk in select patient populations but may not always be an appropriate surrogate for clinical end points. In conclusion, although CIMT has clear advantages over alternative cardiovascular imaging modalities, ultimately, prospective trials comparing the effectiveness of CIMT as a predictive tool of cardiovascular risk with that of other novel markers would best direct clinical recommendations for this imaging measure.

UR - http://www.scopus.com/inward/record.url?scp=65249088072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249088072&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2009.01.020

DO - 10.1016/j.amjcard.2009.01.020

M3 - Article

C2 - 19406278

AN - SCOPUS:65249088072

VL - 103

SP - 1316

EP - 1320

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 9

ER -